FiftyOne Capital have just updated their research report on PAR and upgraded outlook with the in-licensing of MPS, and release of substantial additional SAS data since the latest report.
http://www.fiftyonecapital.com/market-insights/2018/11/24/paradigm-biopharmaceuticals-ltd
There is a lot in there to digest! Some really interesting comparisons with other trials, drugs and statistics that support the bull case and the near certain success of the P2 trial. Interesting comparators on deal sizes as a function of market size, to support some very high valuations from here....
Fifty One Capital updated report
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.010(3.57%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 26.5¢ | $281.4K | 1.024M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3499 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 161588 | 8 |
View Market Depth
| Last trade - 16.10pm 21/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
